Pediatric Blood & Cancer · 2015 · 13 citations · 3 references
MedicineHematologyOncologyCell TherapyChemotherapyStem Cell TransplantationCancer ImmunotherapyCancer Stem CellsCytokine-based TherapyHematopoietic Stem Cell TransplantationHematopoietic Stem CellsStem Cell MobilizationChemokine Receptor Cxcr4 AntagonismG-csf TherapyGranulocyte Colony-stimulating Factor MobilizationGranulocyte-macrophage Colony-stimulating Factor MobilizationPediatric Stem Cell MobilizationPlerixafor MobilizationRetrospective Record ReviewStromal Cell-derived Factor 1 Signaling
Previous chemotherapy and radiation exposure can make adequate stem cell mobilisation prior to autologous transplant extremely difficult in paediatrics. Plerixafor, a selective reversible CXCR4 antagonist interferes with CXCR4 interaction with Stromal cell-derived factor 1 alpha (SDF-1). Combination with granulocyte-colony stimulating factor (G-CSF) amplifies G-CSF affects in mobilising haematopoietic stem cells. Whilst licensed for use with G-CSF for enhancement of mobilisation of haematopoietic stem cells in adults, paediatric data for use of plerixafor remain limited. We present a retrospective review of outcomes seen with plerixafor and G-CSF to mobilise stem cells heavily pre-treated paediatric patients with cancer.
3
Amanda F. Cashen, Sandra Lopez, Feng Gao et al. · Biology of Blood and Marrow Transplantation · 2008 · 130 citations · Full text
Medicine, Hematology, Pharmacology +17
Boryana Avramova, Maya Yordanova, Bobev · Drug Design Development and Therapy · 2011 · 16 citations · Full text
Medicine, Hematology, Oncology +15